ALPHA.PA Stock - Pharnext S.A.
Unlock GoAI Insights for ALPHA.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $10,000 | $558 | $84,785 | $39,830 | $252,773 |
| Gross Profit | $-19,338,850 | $2.26M | $3.56M | $-284,720 | $-352,091 |
| Gross Margin | -193388.5% | 404643.2% | 4204.5% | -714.8% | -139.3% |
| Operating Income | $-23,887,582 | $-30,075,350 | $-26,336,850 | $-21,684,180 | $-23,369,920 |
| Net Income | $-27,517,420 | $-38,445,904 | $-30,617,643 | $-21,564,064 | $-23,309,169 |
| Net Margin | -275174.2% | -6889947.0% | -36112.1% | -54140.3% | -9221.4% |
| EPS | $-196.55 | $-10407.66 | $-10068.28 | $-5557.75 | $-7642.35 |
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
Visit WebsiteEarnings History & Surprises
ALPHA.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 30, 2024 | — | — | — | — |
Q2 2024 | Jun 4, 2024 | — | $-20.79 | — | — |
Q4 2023 | Nov 1, 2023 | — | $-16.60 | — | — |
Q2 2023 | Apr 28, 2023 | — | $-26.27 | — | — |
Q4 2022 | Oct 17, 2022 | — | $-25.96 | — | — |
Q2 2022 | Apr 26, 2022 | — | $-23.18 | — | — |
Q4 2021 | Oct 15, 2021 | — | $-18.41 | — | — |
Q2 2021 | Apr 27, 2021 | — | $-16.94 | — | — |
Q4 2020 | Nov 28, 2020 | — | $-12.35 | — | — |
Q2 2020 | Apr 22, 2020 | — | $-14.97 | — | — |
Q4 2019 | Oct 16, 2019 | — | $-16.69 | — | — |
Q2 2019 | Apr 24, 2019 | — | $-7.24 | — | — |
Q4 2018 | Oct 25, 2018 | — | $-7.24 | — | — |
Q2 2018 | Apr 13, 2018 | — | $-6.88 | — | — |
Q4 2017 | Oct 20, 2017 | — | $-6.88 | — | — |
Q2 2017 | Apr 25, 2017 | — | $-5.93 | — | — |
Q4 2016 | Oct 27, 2016 | — | $-5.93 | — | — |
Q2 2016 | Jun 27, 2016 | — | $-7.90 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-7.03 | — | — |
Q1 2015 | Jan 31, 2015 | — | $-8.23 | — | — |